Electric Vehicle Leaders Urge EU To Maintain 2035 Zero Emission Mandate

by THEFUTURE.TEAM

September 13, 2025

Industry Voices Emphasize the Importance of Commitment

Over 150 key figures from Europe’s electric car sector, including executives from Volvo Cars and Polestar, have signed a letter urging the European Union to adhere to its ambitious 2035 zero emission goal for cars and vans. These industry leaders warn that any deviation could hamper the progress of Europe’s burgeoning EV market, inadvertently strengthen global competitors, and weaken investor confidence.

Evolving Perspectives Within the Automotive Community

This call comes in the wake of a contrasting appeal issued at the end of August by heads of European automobile manufacturers’ and automotive suppliers’ associations. That letter, endorsed by the CEO of Mercedes-Benz, Ola Kaellenius, argued that a 100 percent emission reduction target may no longer be practical for cars by 2035.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Discussion With EU Leadership on The Horizon

European Commission President Ursula von der Leyen is scheduled to meet with automotive industry leaders on September 12 to deliberate the future of the sector. Facing stiff challenges such as the rise of Chinese competition and the implications of US tariffs, the stakes for the EU’s policy decisions have never been higher.

Potential Risks of Eroding Ambitious Targets

Industry leaders like Michael Lohscheller, CEO of Polestar, caution that any weakening of the targets could undermine climate objectives and compromise Europe’s competitive edge in the global market. Michiel Langzaal, chief executive of EU charging provider Fastned, further highlighted that investments in charging infrastructure and software development are predicated on the certainty of these targets.

Regulatory Compliance And The Mercedes-Benz Exception

A report from transport research and campaign group T&E indicates that nearly all European carmakers, with the exception of Mercedes-Benz, are positioned to meet CO₂ regulation requirements for the 2025-2027 period. To avoid potential penalties, Mercedes must now explore cooperation with partners such as Volvo Cars and Polestar.

Conclusion

The industry’s unified stance underscores the critical balance between environmental aspirations and maintaining competitive advantage. With high-level discussions imminent, the EU’s forthcoming decisions will be pivotal in shaping not only the future of the continent’s automotive sector but also its global positioning in the race towards sustainable mobility.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Breaking news